Payer and Provider Webinar for Advancing Patients through Cellular Therapy Treatment
This webinar from May 21, 2025, provides an update on navigating emerging and evolving cellular therapies, with a focus on which patients may be appropriate for cellular therapy treatment. It covers an overview of cellular therapy treatment options, expanding the role of cell therapies in multiple myeloma, updates on gene therapy at Dana-Farber, and best practices for working together to ensure patients receive timely access to necessary care.
0:00 – Welcome, Introduction
Kidest Mequanent, MHA
Network Manager, Cell Therapies
2:06 – Understanding Cellular Therapy Treatment Options: Autologous Stem Cell Transplant, CAR T-cell Therapy, and Bispecific Antibody Therapy
Caron Jacobson, MD, MMSc
Medical Director, Immune Effector Cell Therapy Program
24:03 – Determining Cellular Therapy Treatment for Patients with Multiple Myeloma
Omar Nadeem, MD
Clinical Director, Myeloma Immune Effector Cell Therapy Program and Center for Early Detection and Interception of Blood Cancers
42:35 – Update on Gene Therapy at Dana-Farber
Amar Kelkar, MD
Lead Faculty Clinician for Adult Gene Edited Stem Cell Transplant
56:36 – Overall Payer Challenges from the Financial Perspective
Pat Kelley, BSN, RN
Associate Director, Clinical Service Authorizations